Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1026706
Drug: Placebo

First Posted Date: 2016-01-15

Last Posted Date: 2019-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 57

Registration Number: NCT02657408

Locations: 🇩🇪
Fraunhofer ITEM, Hannover, Germany

Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1026706

First Posted Date: 2016-01-11

Last Posted Date: 2019-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02652416

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan

Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BI 1026706
Drug: Placebo

First Posted Date: 2015-12-30

Last Posted Date: 2019-08-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT02642614

Locations: 🇩🇪
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany
🇩🇪
Fraunhofer ITEM, Hannover, Germany
🇸🇪
Skånes universitetssjukhus, Lund, Lund, Sweden

and more 7 locations

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695501

First Posted Date: 2015-12-29

Last Posted Date: 2018-12-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 430

Registration Number: NCT02640612

Locations: 🇺🇸
Accurate Clinical Research, Inc., Lincoln, Nebraska, United States
🇵🇱
Medical Centre Pratia Warszawa, Warszawa, Poland
🇺🇦
M.V. Sklifosovskyi Poltava RCH, Poltava, Poltava, Ukraine

and more 84 locations

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695501 Autoinjector
Drug: BI 695501 Prefilled syringe

First Posted Date: 2015-12-22

Last Posted Date: 2018-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 77

Registration Number: NCT02636907

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇵🇱
Wojewodzki Szpital Zespolony w Elblagu, Elblag, Poland
🇵🇱
Medica Pro Familia Spolka Akcyjna, Oddzial w Gdyni, Gdynia, Poland

and more 16 locations

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Donepezil

First Posted Date: 2015-12-21

Last Posted Date: 2024-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02635750

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Decitabine
Drug: BI 836858

First Posted Date: 2015-12-17

Last Posted Date: 2024-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02632721

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇩🇪
Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany

and more 11 locations

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Empagliflozin
Drug: Placebo (matching empagliflozin)
Drug: ramipril

First Posted Date: 2015-12-17

Last Posted Date: 2020-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02632747

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran
Drug: Warfarin

First Posted Date: 2015-12-15

Last Posted Date: 2018-03-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4313

Registration Number: NCT02631057

Locations: 🇯🇵
NISED Center, Tokyo, Shinagawa, Japan
🇯🇵
1160.254.81001 Boehringer Ingelheim Investigational Site, Shinagawa, Japan

Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium
Drug: olodaterol

First Posted Date: 2015-12-15

Last Posted Date: 2019-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 184

Registration Number: NCT02629965

Locations: 🇯🇵
Tohno Chuo Clinic, Gifu, Mizunami, Japan
🇯🇵
Kirigaoka Tsuda Hospital, Fukuoka, Kitakyushu, Japan
🇯🇵
Nishi Fukuoka Hospital, Fukuoka, Fukuoka, Japan

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy